JMP Securities analyst Donald Ellis reiterated an Outperform rating and $4 price target on Clearside Biomedical after the FDA agreed to accept clinical use data from the macular edema associated with the RVO study, removing the need for an additional clinical use study for the uveitis NDA. The analyst tells investors in a research note that Clearside plans to resubmit the NDA for XIPERE in non-infectious uveitis in 2Q20 and expects an FDA review within six months of submission. He expects Clearside's cash to last until at least the third quarter, but adds that removing the need for the clinical use study likely extends the cash runway.